Cargando…

Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients

BACKGROUND: Continuous infusion of vancomycin is increasingly preferred as an alternative to intermittent administration in critically ill patients. Intermittent vancomycin treatment is associated with an increased occurrence of nephrotoxicity. This study was designed to determine the incidence and...

Descripción completa

Detalles Bibliográficos
Autores principales: Spapen, Herbert D, Janssen van Doorn, Karin, Diltoer, Marc, Verbrugghe, Walter, Jacobs, Rita, Dobbeleir, Nadia, Honoré, Patrick M, Jorens, Philippe G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224465/
https://www.ncbi.nlm.nih.gov/pubmed/21906376
http://dx.doi.org/10.1186/2110-5820-1-26
_version_ 1782217390547795968
author Spapen, Herbert D
Janssen van Doorn, Karin
Diltoer, Marc
Verbrugghe, Walter
Jacobs, Rita
Dobbeleir, Nadia
Honoré, Patrick M
Jorens, Philippe G
author_facet Spapen, Herbert D
Janssen van Doorn, Karin
Diltoer, Marc
Verbrugghe, Walter
Jacobs, Rita
Dobbeleir, Nadia
Honoré, Patrick M
Jorens, Philippe G
author_sort Spapen, Herbert D
collection PubMed
description BACKGROUND: Continuous infusion of vancomycin is increasingly preferred as an alternative to intermittent administration in critically ill patients. Intermittent vancomycin treatment is associated with an increased occurrence of nephrotoxicity. This study was designed to determine the incidence and risk factors of acute kidney injury (AKI) during continuous infusion of vancomycin. METHODS: This was a retrospective, observational, two-center, cohort study in patients with microbiologically documented Gram-positive pneumonia and/or bacteremia and normal baseline renal function. Vancomycin dose was adjusted daily aiming at plateau concentrations of 15-25 μg/mL. AKI was defined as an increase in serum creatinine of 0.3 mg/dL or a 1.5 to 2 times increase from baseline on at least 2 consecutive days after the initiation of vancomycin. Primary data analysis compared patients with AKI with patients who did not develop AKI. A binary logistic regression analysis using the forward stepwise method was used to assess the risk factors associated with AKI. RESULTS: A total of 129 patients were studied of whom 38 (29.5%) developed AKI. Patients with AKI had higher body weight (77.3 ± 15 vs. 70.5 ± 15.2 kg; p = 0.02), more diabetes (79% vs. 54%; p = 0.01), and a higher vasopressor need (87% vs. 59%; p = 0.002). Serum vancomycin levels, body weight, and SAPS 3 score were identified as variables contributing to AKI. The incidence of AKI increased substantially when treatment duration was prolonged (14.9 ± 9.8 vs. 9.2 ± 4.9 days; p = 0.05) and plasma levels exceeded 30 μg/mL. CONCLUSIONS: AKI is frequently observed during continuous vancomycin infusion, particularly when conditions that cause acute (shock) or chronic (diabetes) renal dysfunction are present and vancomycin levels above target range are achieved. Although this study challenges the concept that continuous vancomycin infusion might alleviate the risk of nephrotoxicity in critically ill patients, a direct relationship between vancomycin and nephrotoxicity remains to be proven.
format Online
Article
Text
id pubmed-3224465
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-32244652011-12-16 Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients Spapen, Herbert D Janssen van Doorn, Karin Diltoer, Marc Verbrugghe, Walter Jacobs, Rita Dobbeleir, Nadia Honoré, Patrick M Jorens, Philippe G Ann Intensive Care Research BACKGROUND: Continuous infusion of vancomycin is increasingly preferred as an alternative to intermittent administration in critically ill patients. Intermittent vancomycin treatment is associated with an increased occurrence of nephrotoxicity. This study was designed to determine the incidence and risk factors of acute kidney injury (AKI) during continuous infusion of vancomycin. METHODS: This was a retrospective, observational, two-center, cohort study in patients with microbiologically documented Gram-positive pneumonia and/or bacteremia and normal baseline renal function. Vancomycin dose was adjusted daily aiming at plateau concentrations of 15-25 μg/mL. AKI was defined as an increase in serum creatinine of 0.3 mg/dL or a 1.5 to 2 times increase from baseline on at least 2 consecutive days after the initiation of vancomycin. Primary data analysis compared patients with AKI with patients who did not develop AKI. A binary logistic regression analysis using the forward stepwise method was used to assess the risk factors associated with AKI. RESULTS: A total of 129 patients were studied of whom 38 (29.5%) developed AKI. Patients with AKI had higher body weight (77.3 ± 15 vs. 70.5 ± 15.2 kg; p = 0.02), more diabetes (79% vs. 54%; p = 0.01), and a higher vasopressor need (87% vs. 59%; p = 0.002). Serum vancomycin levels, body weight, and SAPS 3 score were identified as variables contributing to AKI. The incidence of AKI increased substantially when treatment duration was prolonged (14.9 ± 9.8 vs. 9.2 ± 4.9 days; p = 0.05) and plasma levels exceeded 30 μg/mL. CONCLUSIONS: AKI is frequently observed during continuous vancomycin infusion, particularly when conditions that cause acute (shock) or chronic (diabetes) renal dysfunction are present and vancomycin levels above target range are achieved. Although this study challenges the concept that continuous vancomycin infusion might alleviate the risk of nephrotoxicity in critically ill patients, a direct relationship between vancomycin and nephrotoxicity remains to be proven. Springer 2011-07-19 /pmc/articles/PMC3224465/ /pubmed/21906376 http://dx.doi.org/10.1186/2110-5820-1-26 Text en Copyright ©2011 Spapen et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Spapen, Herbert D
Janssen van Doorn, Karin
Diltoer, Marc
Verbrugghe, Walter
Jacobs, Rita
Dobbeleir, Nadia
Honoré, Patrick M
Jorens, Philippe G
Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title_full Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title_fullStr Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title_full_unstemmed Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title_short Retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
title_sort retrospective evaluation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224465/
https://www.ncbi.nlm.nih.gov/pubmed/21906376
http://dx.doi.org/10.1186/2110-5820-1-26
work_keys_str_mv AT spapenherbertd retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT janssenvandoornkarin retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT diltoermarc retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT verbrugghewalter retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT jacobsrita retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT dobbeleirnadia retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT honorepatrickm retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients
AT jorensphilippeg retrospectiveevaluationofpossiblerenaltoxicityassociatedwithcontinuousinfusionofvancomycinincriticallyillpatients